|
AU2020257053A1
|
|
Cell engaging binding molecules
|
|
WO2021071319A1
|
|
Multispecific fusion protein and use thereof
|
|
WO2021044014A1
|
|
Anti-vsig4 antibody or antigen binding fragment and uses thereof
|
|
KR20210006637A
|
|
Antibody specifically binding to B7-H3(CD276) and Use thereof
|
|
EP3816187A1
|
|
Monoclonal antibody specifically binding to lag-3 and use thereof
|
|
KR20200125213A
|
|
Bispecific Antibody Against IL-17A and TNF-α
|
|
WO2019197979A1
|
|
Cell engaging binding molecules
|
|
US2019309094A1
|
|
Cell engaging binding molecules
|
|
EP3683236A2
|
|
Antibody against human dlk1 and use thereof
|
|
KR20190053464A
|
|
Antibodies Specifically Binding Against IL-17A and Uses Thereof
|
|
WO2019066093A1
|
|
Scf-specific antibody
|
|
AU2017306507A1
|
|
Antibody to programmed death-ligand 1 (PD-L1) and use thereof
|
|
CN110049998A
|
|
For the new antibodies and application thereof of apoptosis 1 (PD-1)
|
|
WO2018026249A1
|
|
Antibody against programmed death-ligand 1 (pd-l1), and use thereof
|
|
WO2018026248A1
|
|
Novel antibody against programmed cell death protein (pd-1), and use thereof
|
|
KR20180096072A
|
|
Novel Multi-Specific Binding Proteins
|
|
KR20180092072A
|
|
Antibody Libraries Having high performance, high productivity and Methods for Preparation of Them
|
|
US2017121380A1
|
|
Composition for preventing or treating fatty liver or insulin resistance syndrome including extracellular domain of delta-like 1 homolog
|
